Crinetics Pharmaceuticals (CRNX) Equity Ratio (2017 - 2026)

Crinetics Pharmaceuticals has reported Equity Ratio for 10 years, with the latest figure at 0.91 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio fell 0.79% year-over-year to 0.91; the trailing twelve-month figure through Mar 2026 stood at 0.91 (down 0.79% YoY), and the FY2025 full-year result was 0.88, down 4.61% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.91, up from 0.88 in the prior quarter.
• The five-year high for Equity Ratio was 0.92 in Q4 2024, with the low at 0.85 in Q4 2023.
• Average Equity Ratio over 5 years is 0.89, with a median of 0.9 recorded in 2025.
• Year-over-year, Equity Ratio retreated 6.48% in 2023 and gained 8.83% in 2024.
• Tracing CRNX's Equity Ratio over 5 years: stood at 0.9 in 2022, then declined by 5.53% to 0.85 in 2023, then advanced by 8.83% to 0.92 in 2024, then declined by 4.61% to 0.88 in 2025, then advanced by 3.75% to 0.91 in 2026.
• The last three Equity Ratio figures came in at 0.91 (Q1 2026), 0.88 (Q4 2025), and 0.9 (Q3 2025), per Business Quant data.

Peer Comparison